Lian Wang

Lian Wang

Auto-generated profile, based on publicly available information

Lian Wang

Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LWLian Wang
Lian Wang
YZYanghui Zhu
Yanghui Zhu
LZLu Zhang
Lu Zhang
LGLinghong Guo
Linghong Guo
XWXiaoyun Wang
Xiaoyun Wang
GHGu He
Gu He
Pyroptosis, apoptosis, and necroptosis are mainly programmed cell death (PCD) pathways for host defense and homeostasis. PANoptosis is a newly distinct inflammatory PCD pathway that is uniquely regulated by multifaceted PANoptosome complexes and highlights significant crosstalk and coordination among pyroptosis (P), apoptosis (A), and/or necroptosis(N). Although some studies have focused on the possible role of PANpoptosis in diseases, the pathogenesis of PANoptosis is complex and underestimated. Furthermore, the progress of PANoptosis and related agonists or inhibitors in disorders has not yet been thoroughly discussed. In this perspective, we provide perspectives on PANoptosome and PANoptosis in the context of diverse pathological conditions and human diseases. The treatment targeting on PANoptosis is also summarized. In conclusion, PANoptosis is involved in plenty of disorders including but not limited to microbial infections, cancers, acute lung injury/acute respiratory distress syndrome (ALI/ARDS), ischemia-reperfusion, and organic failure. PANoptosis seems to be a double-edged sword in diverse conditions, as PANoptosis induces a negative impact on treatment and prognosis in disorders like COVID-19 and ALI/ARDS, while PANoptosis provides host protection from HSV1 or Francisella novicida infection, and kills cancer cells and suppresses tumor growth in colorectal cancer, adrenocortical carcinoma, and other cancers. Compounds and endogenous molecules focused on PANoptosis are promising therapeutic strategies, which can act on PANoptosomes-associated members to regulate PANoptosis. More researches on PANoptosis are needed to better understand the pathology of human conditions and develop better treatment.

16 September 2019 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
LWLian Wang
Lian Wang
XWXiang Wen
Xiang Wen
DHDan Hao
Dan Hao
YLYong Li
Yong Li
DDDan Du
Dan Du
XJXian Jiang
Xian Jiang

20 August 2018 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
LWLian Wang
Lian Wang
XJXian Jiang
Xian Jiang
NZNan Zhang
Nan Zhang
LLLian Liu
Lian Liu
HZHui Zhou
Hui Zhou
HLHong‐Jie Liu
Hong‐Jie Liu

27 April 2018 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
YDYing Deng
Ying Deng
DXDeng-mei Xia
Deng-mei Xia
LWLian Wang
Lian Wang
MLMengmeng Li
Mengmeng Li
WLWei Li
Wei Li

17 September 2018 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
LWLian Wang
Lian Wang
NZNan Zhang
Nan Zhang
XLXiao-Xue Li
Xiao-Xue Li
XJXian Jiang
Xian Jiang
Macular amyloidosis and lichenoid amyloidosis are the types of primary cutaneous amyloidosis, characterized by deposition of amyloid in the upper dermis, without other cutaneous or systemic disorders. Clinically, the association of macular amyloidosis and lichenoid amyloidosis is termed biphasic amyloidosis. Patients with facial involvement are rare but they are likely to experience low self‐esteem. Although there are various therapeutic modalities, none is completely satisfactory. Previous studies described macular amyloidosis and lichenoid amyloidosis were associated with apoptosis of keratinocytes. As salicylic acid is an excellent keratinizing agent, we applied salicylic acid in a patient who was diagnosed as biphasic amyloidosis with facial involvement. To our knowledge, this is the first report that biphasic amyloidosis with facial involvement had obvious improvement after treatment of 30% salicylic acid.